Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease
| Autor: | Gerrit van Hall, Thomas Idorn, Bo Feldt-Rasmussen, Iain Bressendorff, Bolette Hartmann, Casper Rydahl, Nicolai J. Wewer Albrechtsen, Lisbet Brandi, Jens J. Holst, Henrik Post Hansen, Morten B. Jørgensen, Mads Hornum, Filip K. Knop |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Denmark Endocrinology Diabetes and Metabolism medicine.medical_treatment Clinical Biochemistry 030232 urology & nephrology Incretin 030209 endocrinology & metabolism Incretins Biochemistry Glucagon End stage renal disease Impaired glucose tolerance Islets of Langerhans 03 medical and health sciences 0302 clinical medicine Endocrinology Double-Blind Method Glucagon-Like Peptide 1 Renal Dialysis Internal medicine Insulin Secretion medicine Humans Insulin Glucose homeostasis Glucose tolerance test medicine.diagnostic_test business.industry Biochemistry (medical) Glucose Tolerance Test Middle Aged Glucose clamp technique medicine.disease Glucose Clamp Technique Kidney Failure Chronic Female business hormones hormone substitutes and hormone antagonists |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 105:e564-e574 |
| ISSN: | 1945-7197 0021-972X |
| Popis: | Context The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). Objective To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. Design and Setting Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. Results During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8–72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13–50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. Conclusions The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|